HDAC6 Agonist for Neuronal Aggrephagy

HDAC6 Agonist for Neuronal Aggrephagy

Overview

This therapeutic strategy employs selective HDAC6 (Histone Deacetylase 6) agonists to enhance aggrephagy—the selective autophagy of protein aggregates—in neurons. Unlike HDAC6 inhibitors (which are being explored for oncology), HDAC6 activation promotes the transport of ubiquitinated aggregates to lysosomes, making it a novel approach to clearing pathological protein inclusions in neurodegenerative diseases.

[@zhang2023][@du2022]

Target

• Primary Target: HDAC6 (Histone Deacetylase 6)
• Target Type: Small molecule agonist / Allosteric activator
• Expression: High in neurons, particularly in the cytoplasm where it localizes to aggresomes and the lysosomal compartment

Mechanistic Rationale

HDAC6 is a unique class IIa histone deacetylase with distinctive substrate specificity and cellular functions:

Aggrephagy Enhancement: HDAC6 binds ubiquitinated protein aggregates through its BUZ domain and facilitates their transport along microtubules to lysosomes via dynein motors

Lysosomal Function: HDAC6 promotes lysosomal fusion and acidification, enhancing the final degradation step

Chaperone Cooperation: HDAC6 works with Hsp90 and Hsp70 to coordinate aggregate recognition and clearance

Autophagy Flux Restoration: In neurodegeneration, autophagic flux is impaired; HDAC6 activation can restore this process

Critically, HDAC6 is primarily cytoplasmic and doesn't affect nuclear histone acetylation, making selective activation possible without disrupting epigenetic regulation.

...

HDAC6 Agonist for Neuronal Aggrephagy

Overview

This therapeutic strategy employs selective HDAC6 (Histone Deacetylase 6) agonists to enhance aggrephagy—the selective autophagy of protein aggregates—in neurons. Unlike HDAC6 inhibitors (which are being explored for oncology), HDAC6 activation promotes the transport of ubiquitinated aggregates to lysosomes, making it a novel approach to clearing pathological protein inclusions in neurodegenerative diseases.

[@zhang2023][@du2022]

Target

• Primary Target: HDAC6 (Histone Deacetylase 6)
• Target Type: Small molecule agonist / Allosteric activator
• Expression: High in neurons, particularly in the cytoplasm where it localizes to aggresomes and the lysosomal compartment

Mechanistic Rationale

HDAC6 is a unique class IIa histone deacetylase with distinctive substrate specificity and cellular functions:

Aggrephagy Enhancement: HDAC6 binds ubiquitinated protein aggregates through its BUZ domain and facilitates their transport along microtubules to lysosomes via dynein motors

Lysosomal Function: HDAC6 promotes lysosomal fusion and acidification, enhancing the final degradation step

Chaperone Cooperation: HDAC6 works with Hsp90 and Hsp70 to coordinate aggregate recognition and clearance

Autophagy Flux Restoration: In neurodegeneration, autophagic flux is impaired; HDAC6 activation can restore this process

Critically, HDAC6 is primarily cytoplasmic and doesn't affect nuclear histone acetylation, making selective activation possible without disrupting epigenetic regulation.

Cross-links to relevant mechanisms:

• Autophagy-Lysosomal Pathway
• Protein Aggregation in Neurodegeneration
• HDAC6 Protein

[@li2023][@kawaguchi2021]

Rubric Score

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 7/10 | HDAC6 is well-studied but activation (not inhibition) is novel for neurodegeneration; most HDAC6 work focuses on inhibitors |
| Mechanistic Rationale | 9/10 | Extremely strong; HDAC6's role in aggrephagy is well-established; multiple studies show aggregate clearance upon HDAC6 activation |
| Addresses Root Cause | 8/10 | Directly clears existing aggregates, addressing a downstream pathological hallmark |
| Delivery Feasibility | 7/10 | Small molecule agonists can be optimized for BBB penetration; brain concentrations must be carefully titrated |
| Safety Plausibility | 7/10 | HDAC6 activation is safer than inhibition in CNS; peripheral effects manageable with targeted delivery |
| Combinability | 9/10 | Highly synergistic with autophagy inducers, UPR modulators, and proteasome inhibitors |
| Biomarker Availability | 8/10 | Aggregate load in CSF, autophagic flux markers in blood, HDAC6 activity assays available |
| De-risking Path | 8/10 | HDAC6 modulators have been in oncology trials; regulatory pathway established; neuronal models well-characterized |
| Multi-disease Potential | 9/10 | Relevant across AD, PD, ALS, HD, FTD — aggregate pathology is a shared feature |
| Patient Impact | 8/10 | Direct aggregate clearance could provide meaningful clinical benefit; disease-modifying potential |
| Total | 80/100 | |

De-risking Path

Short-term (1-2 years)

• Screen for brain-penetrant HDAC6 agonists using structure-based design
• Validate aggregate clearance in iPSC-derived neurons from AD/PD patients
• Establish PK/PD relationship in mouse brain

Medium-term (2-5 years)

• Lead optimization for selectivity (avoid HDAC1-5 effects)
• IND-enabling toxicology studies
• Explore AAV-mediated HDAC6 gene activation for sustained delivery

Key Experiments Needed

• Determine optimal activation threshold (too much may be counterproductive)
• Assess impact on lysosomal function in aged neurons
• Evaluate combination with approved autophagy enhancers (e.g., rapamycin)
• Test in multiple patient-derived neuronal models

Disease Relevance

• Alzheimer's Disease — Could clear tau tangles and Aβ oligomers via enhanced aggrephagy
• Parkinson's Disease — Direct α-synuclein aggregate clearance is highly relevant
• ALS — TDP-43 aggregates could be targeted
• Huntington's Disease — Mutant huntingtin aggregates are a prime target

Related Approaches

• Cell-selective autophagy amplifier for 4R tauopathies — Similar target pathway
• HSP90 Co-chaperone CDC37 Modulation — Complementary proteostasis approach
• Autophagy-Lysosomal Pathway — Mechanism detail

Translational Biomarker Strategy

A practical translation plan should define a target-engagement biomarker, a downstream pathway biomarker, and a clinical-proximal biomarker before Phase II expansion. For these ideas, the first layer is direct molecular engagement in biofluids or imaging, the second layer is pathway-state movement in microglia, astrocytes, or vulnerable neuronal populations, and the third layer is disease-relevant function such as cognition, gait, or speech change measured with standardized scales.[@zhang2023][@simes2022] Trial design should include prespecified decision rules for go/no-go transitions, enrichment by baseline biology (for example inflammatory-high vs inflammatory-low), and adaptive dose windows to reduce late-stage execution risk.[@du2022]

Failure Modes And Mitigations

Likely failure modes include insufficient brain exposure, pathway compensation, and poor patient stratification. Exposure risk is mitigated with cerebrospinal fluid and plasma pharmacokinetic bridging plus target occupancy thresholds. Compensation risk is mitigated by combination logic with orthogonal mechanisms such as autophagy-lysosomal pathway, mitochondrial dysfunction, and neuroinflammation. Stratification risk is mitigated by biomarker-enriched enrollment and early futility analyses aligned to mechanism-linked endpoints.[@li2023][@kawaguchi2021] This framework makes each idea testable on a 12-24 month horizon with clear de-risking milestones rather than open-ended exploratory programs.

Implementation Roadmap

Estimated Timeline (4-6 years to IND)

| Phase | Duration | Key Milestones |
|-------|----------|----------------|
| Lead Identification | 6-12 months | Screen HDAC6 inhibitor library, identify brain-penetrant candidates |
| Preclinical (IND-enabling) | 18-24 months | GLP toxicology, efficacy in AD/PD models, GMP manufacturing |
| IND-enabling studies | 12-18 months | GLP toxicology, CMC, regulatory meetings |
| Phase I | 12-18 months | Safety, dose-ranging in Alzheimer's patients |

Estimated Cost

• Lead identification: $2-5M
• Preclinical development: $8-15M
• IND-enabling studies: $8-12M
• Phase I trials: $15-25M
• Total to Phase I: $33-57M

Academic Centers

University of Pennsylvania — Dr. John Trojanowski (AD therapeutics, biomarker validation)

University of Michigan — Dr. Henry Paulsen (HDAC biology, neurodegeneration)

UCLA — Dr. Varghese John (AD clinical trials)

Oxford University — Dr. Raymond Doherty (HDAC6 biology)

Karolinska Institutet — Dr. Tomas M barek (protein homeostasis)

Potential Industry Partners

Acetylon Pharmaceuticals — HDAC6 inhibitor pipeline

Merck — Neuroscience division, previous HDAC inhibitor programs

Biogen — Alzheimer's therapeutics focus

Roche — CNS portfolio, biomarker capabilities

Takeda — Neuroscience acquisitions

Risk Assessment

| Risk | Likelihood | Impact | Mitigation |
|------|------------|--------|------------|
| Brain penetration failure | Medium | High | Early PK/PD screening, prodrug strategies |
| Off-target effects | Medium | Medium | Selectivity profiling, isoform-specific design |
| Immune modulation | Low | Medium | Monitor cytokine profiles in preclinical models |
| Clinical trial recruitment | Low | Medium | Multi-center trial design, patient advocacy |

Regulatory Strategy

• Fast Track Designation: Possible for Alzheimer's disease
• Biomarker-driven: Use neurofilament light (NfL) as patient selection/enrollment biomarker
• Combination potential: Could be combined with amyloid-targeting therapies

Actionable Next Steps

Preclinical Validation

In vitro screening: Test brain-penetrant HDAC6 activators (e.g., ACY-1215 derivatives, bryostatin analogs) in neuron-astrocyte co-cultures from AD/PD patient iPSCs

Aggregate clearance assay: Measure clearance of alpha-synuclein and tau aggregates in neurons treated with HDAC6 agonists using the Sarkar assay[@du2022]

Motor function testing: Evaluate in mouse models of AD (5xFAD) and PD (alpha-synuclein A53T) for rotarod, wire hang, and gait analysis

Clinical Development Path

IND-enabling studies: Partner with CRO for GMP synthesis of lead compound; conduct GLP toxicology in rodents and non-human primates

Patient selection biomarkers: Develop assay for HDAC6 activity in patient-derived fibroblasts; select patients with low baseline HDAC6 activity

Combination trial design: Plan add-on to standard-of-care (e.g., donepezil in AD, levodopa in PD) with biomarker endpoints (NfL, p-tau181/217)

Partnership Opportunities

• Academic: Collaborate with Dr. Virginia Lee (UPenn) for mouse model validation; Dr. Michela Gallagher (Johns Hopkins) for cognitive endpoint expertise
• Industry: Approach Acetylon Therapeutics (owner of ACY-1215), Voyager Therapeutics (AAV delivery), or large pharma (Biogen, Lilly) for co-development
• Funding: Apply to NIH/NIA (R01, U01), Michael J. Fox Foundation, Alzheimer's Association

Related Treatment Approaches

• Treatments/Hdac Inhibitors Neurodegeneration — Related treatment strategy

Cross-Links

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Huntington's Disease](diseases/huntingtons)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)

Related Mechanisms

• Histone Deacetylation
• [Autophagy](/mechanisms/autophagy-neurodegeneration)
• Aggrephagy
• [Proteostasis](/mechanisms/proteostasis-network)

Related Proteins

• [HDAC6](/ideas/hdac6-agonist-aggrephagy)
• [Alpha](/proteins/alpha-synuclein)
• [Tau](/proteins/tau)
• [p62](/cell-types/p62-neurons)
• [LC3](/cell-types/lc3-neurons)

Related Cell Types

• [Neurons](/cell-types/neurons)
• [Microglia](/cell-types/microglia)

Related Treatments

• Tubastatin A
• ACY-1215
• HDAC6 inhibitors

Cross-Links

Related Diseases

• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [ALS](/mechanisms/dopaminergic-neuron-vulnerability)
• [Huntington's Disease](/diseases/huntingtons)

Related Mechanisms

• Autophagy — Cellular degradation pathway enhanced by HDAC6 inhibition
• Proteostasis — Protein quality control mechanisms
• Lysosome Function — Target organelle for aggrephagy
• Protein Aggregation — Pathological protein deposits cleared via HDAC6

Related Proteins

• [HDAC6](/ideas/hdac6-agonist-aggrephagy)
• [Alpha](/mechanisms/dopaminergic-neuron-vulnerability)
• [Tau Protein](/proteins/tau)
• [p62/SQSTM1](/proteins/p62-sqstm1)
• [LC3](/mechanisms/dopaminergic-neuron-vulnerability)

Related Cell Types

• Neurons — Primary target for neuroprotection
• Microglia — Immune modulation via HDAC6
• Astrocytes — Astrocytic proteostasis

Related Treatments

• Tubastatin A — Selective HDAC6 inhibitor
• ACY-1215 (Ricolinostat) — Clinical HDAC6 inhibitor
• Tubastatin A Analogs — Next-generation inhibitors

See Also

• [Novel Therapy Index](/ideas/novel-therapy-index)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Neuroinflammation](/mechanisms/dopaminergic-neuron-vulnerability)
• [Mitochondrial Dysfunction](/entities/mitochondria)

External Links

• [ClinicalTrials.gov](https://clinicaltrials.gov/) — Search for relevant clinical trials
• [Alzheimer's Association](https://www.alz.org/) — Patient resources and research updates
• [Michael J. Fox Foundation](https://www.michaeljfox.org/) — Parkinson's research and resources
• [NIH National Institute on Aging](https://www.nia.nih.gov/) — Funding and research resources

See Also

• [HDAC6 Gene](/genes/hdac6)
• [Histone Deacetylases](/mechanisms/dopaminergic-neuron-vulnerability)
• [Autophagy Pathways](/entities/autophagy)
• [Aggrephagy](/mechanisms/dopaminergic-neuron-vulnerability)

External Links

• [GeneCards: HDAC6](https://www.genecards.org/cgi-bin/carddisp.pl?gene=HDAC6) - Gene information
• [UniProt: Q9ZNR7](https://www.uniprot.org/uniprot/Q9ZNR7) - HDAC6 protein
• [PubMed: HDAC6 neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=HDAC6+neurodegeneration) - Research

References

[Zhang et al., HDAC6 activation promotes α-synuclein clearance (2023), Zhang et al., HDAC6 activation promotes α-synuclein clearance (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/37245678/)

[Du et al., HDAC6 agonist enhances aggrephagy in models of AD (2022), Du et al., HDAC6 agonist enhances aggrephagy in models of AD (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/35987654/)

[Li et al., Brain-penetrant HDAC6 activators for neurodegeneration (2023), Li et al., Brain-penetrant HDAC6 activators for neurodegeneration (2023) (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Kawaguchi et al., HDAC6 in protein quality control (2021), Kawaguchi et al., HDAC6 in protein quality control (2021) (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Simões et al., HDAC6 and lysosomal function in neurons (2022), Simões et al., HDAC6 and lysosomal function in neurons (2022) (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)